Adar1 Capital Management, Llc Acquires 202,124 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

Posted by Stanley Muller on Aug 26th, 2026

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) major shareholder Adar1 Capital Management, Llc bought 202,124 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was bought at an average price of $1.78 per share, with a total value of $359,780.72. Following the completion of the acquisition, the insider owned 4,030,075 shares in the company, valued at $7,173,533.50. This represents a 5.28% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Monday, August 24th, Adar1 Capital Management, Llc bought 107,374 shares of Tenax Therapeutics stock. The stock was bought at an average cost of $1.75 per share, with a total value of $187,904.50.
On Friday, August 21st, Adar1 Capital Management, Llc purchased 716,369 shares of Tenax Therapeutics stock. The shares were bought at an average price of $1.77 per share, for a total transaction of $1,267,973.13.

Tenax Therapeutics Trading Up 25.4%

Shares of TENX stock opened at $2.32 on Wednesday. The company’s 50-day moving average price is $11.57 and its 200-day moving average price is $12.45. The stock has a market cap of $86.81 million, a price-to-earnings ratio of -1.57 and a beta of 0.93. Tenax Therapeutics, Inc. has a twelve month low of $1.31 and a twelve month high of $19.40.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. As a group, equities research analysts predict that Tenax Therapeutics, Inc. will post -1.41 EPS for the current year.

Hedge Funds Weigh In On Tenax Therapeutics

A number of hedge funds have recently made changes to their positions in TENX. Janus Henderson Group PLC raised its position in Tenax Therapeutics by 989.3% in the first quarter. Janus Henderson Group PLC now owns 1,815,474 shares of the specialty pharmaceutical company’s stock valued at $29,066,000 after purchasing an additional 1,648,808 shares during the period. Perceptive Advisors LLC lifted its stake in Tenax Therapeutics by 229.7% during the first quarter. Perceptive Advisors LLC now owns 1,447,782 shares of the specialty pharmaceutical company’s stock worth $23,150,000 after purchasing an additional 1,008,640 shares in the last quarter. Braidwell LP purchased a new position in shares of Tenax Therapeutics during the second quarter worth $8,503,000. Bank of New York Mellon Corp purchased a new position in shares of Tenax Therapeutics during the second quarter worth $4,733,000. Finally, Diadema Partners LP purchased a new position in shares of Tenax Therapeutics during the fourth quarter worth $2,964,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TENX. Weiss Ratings cut shares of Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group set a $4.00 price target on shares of Tenax Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 11th. Piper Sandler upped their price objective on Tenax Therapeutics from $20.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Evercore lowered Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research report on Tuesday, August 11th. Finally, Roth Capital set a $5.00 target price on Tenax Therapeutics in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Check Out Our Latest Stock Analysis on TENX

Tenax Therapeutics Company Profile

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.